APRI Makes 2nd Try, PRQR To Reveal Data On Sep.25, PFE Awaits FDA Decision

Today's Daily Dose brings you news about Apricus' resolve to get its investigational erectile dysfunction product approved by the FDA; special status granted to Abeona's investigational Epidermolysis Bullosa treatment; upcoming regulatory catalyst of BioMarin and Pfizer; Nasdaq notification for Immune Pharma; ProQR Therapeutics' near-term clinical trial catalyst and Sorrento's second try at gettin

from RTT - Biotech http://ift.tt/2wRWzo7
via IFTTT